Hepsera — Competitive Intelligence Brief

Hepsera (ADEFOVIR DIPIVOXIL) competitive landscape: 5 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor. Area: Infectious Disease.

marketed Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor DNA polymerase subunit gamma-1 Infectious Disease Small molecule

Target snapshot

Hepsera (ADEFOVIR DIPIVOXIL) — Gilead Sciences. Hepsera works by mimicking a building block of DNA, which it uses to trick the Hepatitis B Virus into incorporating faulty genetic material, ultimately halting its replication.

Comparator set (5 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Hepsera TARGET	ADEFOVIR DIPIVOXIL	Gilead Sciences	marketed	Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor	DNA polymerase subunit gamma-1	2002-01-01
Hepsera	Hepsera	Gilead Sciences	marketed		DNA polymerase subunit gamma-1, Capsid protein, Protein P
Tivicay	DOLUTEGRAVIR	GSK	marketed	Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]	Transmembrane protein 97	2013-01-01
ABACAVIR SULFATE	ABACAVIR SULFATE		marketed	Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]		1998-01-01
Epivir	LAMIVUDINE	GSK	marketed	Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]	Deoxycytidine kinase	1995-01-01
Retrovir	ZIDOVUDINE	GSK	marketed	Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]	Thymidine kinase, cytosolic	1987-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor class)

1. Gilead Sciences · 1 drug in this class